

Supplementary material

Table 1S. Chemotherapy regimens with EMA/CO and EM/CO

Day	Drugs	Dose
EMA/CO		
1	Etoposide ActDMTX MTX	100 mg/m ² diluted in 200 ml of saline solution and infused IV over 30 min 0.5 mg IV bolus 100 mg/m ² IV bolus 200 mg/m ² by IV infusion over 12h
2	Etoposide ActD Folinic acid	100 mg/m ² diluted in 200 ml of saline solution and infused IV over 30 min 0.5 mg IV bolus 15 mg IM every 12h (4 doses) or oral route starting 24h after starting MTX
8	Cyclophosphamide Vincristine	600 mg/m ² diluted in saline solution and infused over 30 min 1 mg/m ² bolus IV
EM/CO		
1	Etoposide Cisplatin	150 mg/m ² diluted in 200 ml of saline solution and infused IV over 30 min 75mg/m ² IV with prior hydration
8	Etoposide MTX ActD Folinic acid	100mg/m ² diluted in 200 ml of saline solution and infused IV over 30 min 300mg/m ² by IV infusion over 12h 0.5 mg IV bolus 15 mg IM every 12h (4 doses) or oral route starting 24 h after starting MTX

ActD: actinomycin-D, MTX: methotrexate

Table 2S. Association between chemotherapy regimen used and toxicity and main side effects

	EM/CO (N=33)	EMA/CO (N=109)	p-value
Toxicity	84.8% (28/33)	71.6% (78/109)	0.124 *
Anemia	63.6% (21/33)	69.7% (76/109)	0.510 *
Neutropenia	33.3% (11/33)	24.8% (27/109)	0.330 *
Neuropathy	21.2% (7/33)	12.8% (14/109)	0.235 *
Nausea and vomiting	60.6% (20/33)	56.9% (62/109)	0.704 *
Thrombocytopenia	9.1% (3/33)	10.1% (11/109)	0.866 *
Stomatitis	45.5% (15/33)	46.8% (51/109)	0.893 *
Creatinine elevation	3.0% (1/33)	7.3% (8/109)	0.373 *
Altered liver function	21.2% (7/33)	22.9% (25/109)	0.836 *
Diarrhea	18.2% (6/33)	11.0% (12/109)	0.278 *
Use of granuloquine	54.5% (18/33)	70.6% (77/109)	0.085 *

Chi-squared *: % (n/N). p<0.05

Table 3S. Influence of the chemotherapy regimen used during the first-line treatment in women with a score ≤ 6

	EM/CO (N=20)	EMA/CO (N=49)	OR (95%CI)	p-value
Number of cycles (first-line treatment)	4.8 [2.6]	6.0 [2.4]		0.065 *
Second-line treatment	10.0% (2/20)	16.3% (8/49)	0.56 [0.11-2.88]	0.712 **
Chemoresistance	10.0% (2/20)	16.3% (8/49)	0.56 [0.11-2.88]	0.712 **
Recurrence	10.0% (2/20)	8.2% (4/49)	1.25 [0.22-5.75]	> 0.999 **
Toxicity	80.0% (16/20)	69.4% (34/49)	1.76 [0.51-5.46]	0.553 **
Death	0.0% (0/20)	2.0% (1/49)	0.0 [0.0-22.05]	> 0.999 **

OR: odds ratio; CI: confidence interval. Student's t-test *: mean (standard deviation); Chi-squared **: % (n/N); binary logistic regression. p<0.05

Table 4S. Odds ratio for chemoresistance to first-line chemotherapy treatment

Variable	OR	95%CI	p-value
Pre-treatment serum hCG levels	1.01	1.00-1.01	0.001
Pathology in diagnosis			
Invasive mole	0.39	0.11-1.41	0.154
Choriocarcinoma	2.29	0.90-5.85	0.810
Previous pregnancy			
Molar pregnancy	1.29	0.47-3.52	0.610
Miscarriage	0.00	0.00-Infinite	0.998
Ectopic pregnancy	0.27	0.29-79.99	0.271
Full-term pregnancy	1.47	0.48-4.44	0.495
Use of EM/CO	2.18	0.86-5.53	0.101
Use of EMA/CO	0.46	0.18-1.16	0.101
Prognosis score ≤ 6	0.65	0.27-1.58	0.346
Prognosis score ≥ 7	1.52	0.63-3.67	0.346
Metastases	2.44	0.94-6.28	0.064

OR: odds ratio; CI: confidence interval. Binary logistic regression. p<0.05

Table 5S. Odds ratio for toxicity to chemotherapy treatment

Variable	OR	95%CI	p-value
Number of cycles (first-line treatment)	1.30	1.12-1.52	0.001
Second-line treatment			
No chemotherapy	0.00	0.00-infinite	0.998
EP/EM	infinite	0.00-infinite	0.999
EP/EM + TE/TP	infinite	0.00-infinite	0.999
EP/EMA	infinite	0.00-infinite	0.999
EP/EMA + TE/TP	infinite	0.00-infinite	0.999
TE/TP + ICE	infinite	0.00-infinite	0.999
TE/TP + Pembrolizumab	infinite	0.00-infinite	0.999

OR: odds ratio; CI: confidence interval. Binary logistic regression. P<0.05. EP/EM: etoposide, platinum, etoposide and methotrexate; TE/TP: paclitaxel, etoposide, paclitaxel and platinum; EP/EMA: etoposide, platinum, etoposide, methotrexate and actinomycin-d; ICE: ifosfamide, cyclophosphamide and etoposide